Blood Pro B, Advani R et. al.
Oct 4th, 2017 - This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission, progression-free survival (PFS), overall survival (OS), and safety outcomes of patients treated o...
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Chen R, Zinzani PL et. al.
Apr 25th, 2017 - Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1-blocking antibody, demonstrated a high overall response rate (ORR) in patients with relapsed or refractory classic Hodgkin lymphoma (rrHL) in phase I testing. Methods KEYNOTE-087 ( ClinicalTrials.gov identifie...
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Bröckelmann PJ, Goergen H et. al.
Feb 27th, 2017 - Purpose Clinical characteristics, therapeutic approaches, and prognosis of late relapse (LR) in patients with classic Hodgkin lymphoma (cHL) are poorly understood. We performed a comprehensive analysis of LR of Hodgkin lymphoma (LR-HL). Methods To estimate the incidence of LR-HL, we retrospectively analyzed 6,840 patients with cHL included in the German Hodgkin Study Group trials HD7 to HD12. P...
The New England Journal of Medicine; Roberts AW, Davids MS et. al.
Dec 7th, 2015 - New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells. We conducted a phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL or small lymphocytic lymphoma...
Cancer Therapy Advisor; Thomas M. Habermann
Nov 13th, 2019 - Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma that is potentially curable. DLBCL is the most common non-Hodgkin lymphoma (NHL) representing about 30% of all cases of NHL in the United States of America (USA) and Europe. There are over 76 different types of lymphoma. It is essential to establish the correct histological diagnosis prior to treatment.
Annals of Oncology; Tilly H et al
Nov 13th, 2019 - Diffuse large B-cell lymphoma is relatively common and represents 30%–58% of non-Hodgkin’s lymphomas. The updated ESMO Clinical Practice Guidelines provide information on the current management of diffuse large B-cell lymphoma including recommendations for screening and diagnosis, staging and risk assessment and stage-matched therapeutic strategies including specific recommendations for young a...
Lymphoma Research Foundation;
Nov 6th, 2019 - Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States and worldwide, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are diagnosed with DLBCL each year.
Journal of Cancer; Hu N, et al
Oct 14th, 2019 - DOCK family proteins are evolutionarily conserved guanine nucleotide exchange factors for Rho GTPase with different cellular functions. It has been demonstrated that DOCK1 had adverse prognostic effect in acute myeloid leukemia (AML).
Aug 19th, 2019 - Treatments for children with acute myeloid leukemia and myeloid malignancies include combination chemotherapy, stem cell transplantation, and targeted therapy. Other drug therapy and supportive care is also used. Get detailed information for these diseases in this clinician summary.
Aug 16th, 2019 - Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.1 “The approval of INREBIC is another important milestone for Celgene and underscores our commitment ...
Jul 22nd, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE™ (rituximab-pvvr), a biosimilar to Rituxan® (rituximab),1 for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).2 “Biosimilars like RUXIENCE h...
Jun 30th, 2019 - Acute myeloid leukemias (AMLs) are a heterogeneous group of disorders characterized by the clonal expansion of myeloid blasts (eg, undifferentiated myeloid precursors) in the peripheral blood, bone marrow, and/or other tissues, which results in impaired hematopoiesis and bone marrow failure. 1, 2, 3, 4 AML is the most common acute leukemia in adults (~80% of leukemia cases) and accounts for the...
Williams, M. et. al.
Jun 19th, 2019 - At this year's meeting of the American Society of Clinical Oncology (ASCO 2019), held May 31 to June 4 in Chicago, investigators discussed the latest findings in cancer research. The editors of NEJM Journal Watch Oncology and Hematology were on hand to report highlights of the conference. Here, Michael E. Williams, MD, ScM, reviews key presentations on new treatments for patients with multiple ...
Journal of the National Comprehensive Cancer Network;
Jun 14th, 2019 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guid...
May 27th, 2019 - Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) approved REVLIMID® (lenalidomide) in combination with a rituximab product (R²) for the treatment of adult patients with previously treated follicular lymphoma (FL) or marginal zone lymphoma (MZL) following Priority Review designation. This is the first FDA-approved combination treatment regimen for pa...
May 13th, 2019 - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the outcome of the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) to discuss the company’s New Drug Application (NDA) for quizartinib for the treatment of adults with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML). Three committee members voted yes and 8 committee m...
May 9th, 2019 - TIBSOVO Ivosidenib targets the mutant IDH1 enzyme in R/R AML Learn more about IDH1 testing and the mechanism of action. Visit the site to view full prescribing information, including boxed warning.TIBSOVO is indicated for the treatment of acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.
May 1st, 2019 - Single-agent ivosidenib (Tibsovo) has received FDA approval for the first-line treatment of adult patients with IDH1-mutant acute myeloid leukemia (AML), as detected by an FDA-approved test, who are ≥75 years old or are ineligible to receive intensive chemotherapy.
May 1st, 2019 - On May 2, 2019, the Food and Drug Administration approved ivosidenib (TIBSOVO, Agios Pharmaceuticals, Inc.) for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy.
May 1st, 2019 - Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. Prescribing Information for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor, to include adult patients with newly diagnosed a...